Tool
Tirzepatide First-Month Cost Calculator
This calculator shows what you actually pay on day one — the figure that determines whether you can start — and separates it from the recurring cost that determines whether you can continue. Providers frequently discount the first month, so these two numbers can differ substantially and should be compared separately.
Key takeaways
- First-month cost and recurring cost are different numbers and should be compared separately.
- Introductory discounts make the first month a poor guide to ongoing affordability.
- One-time consultation and setup fees fall entirely in the first month.
- Comparing providers on first-month cost alone systematically favours discount-led offers.
- This tool runs in your browser; nothing you enter is transmitted or stored.
| What it calculates | Amount due at signup versus recurring monthly cost |
|---|---|
| Why they differ | Introductory discounts and one-time fees |
| Risk of comparing first month only | Favours discount-led offers with higher renewal rates |
| Data handling | Runs entirely in your browser |
| Pair with | True-cost calculator |
What you pay to start
Why separate these two numbers?
Because they answer different questions. First-month cost determines whether you can start; recurring cost determines whether you can continue — and continuing is what produces and maintains results. A provider optimising for signups has every incentive to make the first number attractive and the second one less visible.
Comparing providers on the first number alone systematically selects for discount-led offers.
What should you confirm before paying?
The recurring price in writing, including whether the membership rate changes after an introductory period, and whether the medication price itself is introductory. Both are common and both are frequently disclosed only in terms rather than on the pricing page.
Related: True-cost calculator · Cost overview
What do the verified rates look like?
| Group | $/month |
|---|---|
| TRYM Health | 125 |
| NexLife | 186 |
| Fridays | 240 |
| Mochi Health | 278 |
| Eden | 298 |
What does this page cover, and what does it deliberately leave out?
This page addresses Due today, consultation, membership, medication and shipping and renewal, organised around the primary question of tirzepatide first month cost. Each of those elements is treated separately below rather than blended, because they carry different evidence weights and a reader is entitled to know which parts rest on randomised data and which rest on a captured commercial claim or a regulatory document.
| Element | Treatment here | Evidence basis |
|---|---|---|
| Due today | Covered on this page | Regulatory or policy source |
| Consultation | Covered on this page | Regulatory or policy source |
| Membership | Covered on this page | Regulatory or policy source |
| Medication | Covered on this page | Regulatory or policy source |
| Shipping and renewal | Covered on this page | Regulatory or policy source |
| Individualized clinical instruction | Deliberately not covered | Belongs with the provider's own quotation |
What are the limits of what this page can tell you?
Every page on this site rests on a specific figures you enter, and that record has boundaries worth stating plainly rather than leaving a reader to discover them. The limitations below are specific to the material presented above.
- The evidence here describes groups, populations, or captured records — it does not describe you, and no page can substitute for the provider's own quotation.
- Figures carry the date on which they were verified. In a market where terms change frequently, an undated figure functions as a claim about the present that nobody has checked.
- Elements marked Verification Pending are genuinely unknown to this publication rather than merely omitted for brevity, and should not be inferred from surrounding content.
- Where a source conflicts with another, this site shows the conflict rather than resolving it, which means some questions are left open on purpose.
What would change the conclusion on this page?
This conclusion is held open to the following evidence:
- New primary evidence bearing directly on tirzepatide first month cost.
- A change to FDA labelling affecting any statement made above.
- A verified correction submitted through the corrections process and accepted on the evidence.
- A material change to a captured record, including a price, term, or regulatory status.
- Completion of a verification currently marked pending, which would replace a gap with a stated fact.
Frequently asked questions
Why does the first month cost less?
Providers frequently discount the first month or charge a reduced introductory membership to lower the barrier to signing up.
Which number should I compare between providers?
The recurring cost, since that determines whether you can continue treatment.
Is my data stored?
No. The calculation runs in your browser only.
Where do I find the recurring price?
In the provider's written terms or at checkout — often not on the advertised pricing page.
Change history
| Date | Change |
|---|---|
| 2026-07-22 | Page published with current dataset snapshot. |
Dates change only for substantive edits, never for cosmetic changes. Corrections: corrections policy.